Mark Ragosa sold $1.7M of KNSA
CHIEF FINANCIAL OFFICER at Kiniksa Pharmaceuticals International, plc. 36,722 shares at an average of $45.92, traded Mar 9, 2026, filed Mar 11, 2026.
Score components
- +22RoleCFO
- +25Trade size$1.7M at market
- +20Share of holdings soldSold 75% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001835458-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | MOption exercise Class A Ordinary Share10b5-1 | +2,036 | $22.89 | $47k | 14,122 | Mar 11, 2026 |
| Mar 9, 2026 | MOption exercise Class A Ordinary Share10b5-1 | +10,513 | $17.76 | $187k | 24,635 | Mar 11, 2026 |
| Mar 9, 2026 | MOption exercise Class A Ordinary Share10b5-1 | +13,813 | $18.06 | $249k | 38,448 | Mar 11, 2026 |
| Mar 9, 2026 | MOption exercise Class A Ordinary Share10b5-1 | +10,360 | $26.74 | $277k | 48,808 | Mar 11, 2026 |
| Mar 9, 2026 | SOpen-market sale Class A Ordinary Share10b5-1 | -17,981 | $45.58 | $820k | 30,827 | Mar 11, 2026 |
| Mar 9, 2026 | SOpen-market sale Class A Ordinary Share10b5-1 | -18,741 | $46.24 | $867k | 12,086 | Mar 11, 2026 |
| Mar 9, 2026 | MOption exercise Share Optionderivative10b5-1 | -2,036 | $0.00 | $0 | 0 | Mar 11, 2026 |
| Mar 9, 2026 | MOption exercise Share Optionderivative10b5-1 | -10,513 | $0.00 | $0 | 18,396 | Mar 11, 2026 |
| Mar 9, 2026 | MOption exercise Share Optionderivative10b5-1 | -13,813 | $0.00 | $0 | 19,337 | Mar 11, 2026 |
| Mar 9, 2026 | MOption exercise Share Optionderivative10b5-1 | -10,360 | $0.00 | $0 | 22,790 | Mar 11, 2026 |
Related signals
Other insiders at Kiniksa Pharmaceuticals International, plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Kiniksa Pharmaceuticals International, plc | Michael R Megna CHIEF ACCOUNTING OFFICER | $369k 4,600 shares | -14% | |
| 23Weak | Kiniksa Pharmaceuticals International, plc | John F. Paolini CHIEF MEDICAL OFFICER | $1.8M 40,000 shares | -39% | |
| 4Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $126k 2,800 shares | -22% | |
| 37Weak | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $772k 17,845 shares | -60% | |
| 29Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $722k 15,960 shares | -119% | |
| 30Weak | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $503k 12,000 shares | -39% | |
| 38Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $836k 20,129 shares | -62% | |
| 28Weak | Kiniksa Pharmaceuticals International, plc | Eben Tessari CHIEF OPERATING OFFICER | $501k 12,048 shares | -42% | |
| 47Moderate | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $1.8M 42,841 shares | -58% | |
| 0Weak | Kiniksa Pharmaceuticals International, plc | Eben Tessari CHIEF OPERATING OFFICER | $8,578 200 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.